AI assistant
RACURA ONCOLOGY LTD — Call Transcript 2017
Mar 16, 2017
65658_rns_2017-03-16_feb458e4-9664-491f-a940-8a56a0adc457.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [180 x 91] intentionally omitted <==
ASX RELEASE
INVESTOR CONFERENCE CALL RECORDING
17 March 2017: Specialty pharmaceutical company, Race Oncology Ltd (ASX: RAC) is pleased to advise that a recording of the Investor Conference Call hosted on Thursday, 16 March 2017 is now available at the following link: http://www.openbriefing.com/OB/2474.aspx
During the call Race Oncology CEO Peter Molloy provided an update on the important recent developments and the Company’s plans for the coming year.
Further information can also be found in Race Oncology’s updated Investor Presentation released on 9 March 2017.
About Race Oncology
Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company’s goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit raceoncology.com for more information.
For more information, contact:
Peter Molloy T: +61 (0) 3 9097 1656 Managing Director E: [email protected]
Investor Relations
F T I Consulting
T: +61 (0)8 9485 8888